Genetic, Biomarker and Biospecimen Core

遗传、生物标志物和生物样本核心

基本信息

批准号：
10666625
负责人：
TATIANA M. FOROUD
金额：
$ 35.14万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-01 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10666625
关键词：
Address Alzheimer&apos s Disease Alzheimer&apos s disease model Alzheimer&apos s disease related dementia Alzheimer&apos s disease therapeutic Amyloid beta-42 Amyloid beta-Protein Animal Model Area Astrocytes Basic Science Behavioral Biological Markers Blood specimen Clinical Cognitive Collaborations Collection Computerized Medical Record DNA Data Dementia Development Disease Disease susceptibility Education Fostering Generations Genetic Genetic Counseling Genomics Genotype Goals Home Image Impaired cognition Indiana Individual Inherited Link Liquid substance Mentors Microglia Mission Molecular Molecular Genetics Multimodal Imaging Neurons Neurosciences Research Outcome Participant Peripheral Blood Mononuclear Cell Plasma Play RNA Recording of previous events Research Research Institute Research Personnel Risk Factors Role Sampling Serum Specimen Testing Therapeutic Universities Visit Work blood-based biomarker causal variant clinical predictors cohort drug development drug discovery genome resource genome wide association study genomic data imaging genetics induced pluripotent stem cell innovation interest lectures medical schools meetings member mild cognitive impairment mouse model neuroimaging neuropathology normal aging novel therapeutics patient population pre-clinical programs protective factors research study specific biomarkers symptom treatment tau Proteins therapeutic evaluation translational study

项目摘要

Project Summary – Genetics, Biomarker, and Biospecimen Core (GBBC) The Indiana Alzheimer’s Disease Research Center (IADRC) has a strong history of innovative research in molecular and imaging genomics and will continue to focus on the role of genetics and other types of biomarkers as predictors of clinical trajectories among the broader group of individuals with Alzheimer’s disease (AD) and other dementias, as well as those in preclinical and prodromal stages, such as subjective cognitive decline (SCI) and mild cognitive impairment (MCI). The Genetics, Biomarker and Biospecimen Core (GBBC) plays a central role in supporting this overall focus through the collection of uniform biospecimens, coordination of genetic data and generation of blood-based biomarkers. The GBBC also supports multiple national efforts through the broad sharing of specimens and data. The GBBC leverages the unique patient populations and genomics resources at Indiana University School of Medicine to support each Core as well as the overall goals of the IADRC. The GBBC fosters new research directions through the common banking of samples from diverse research groups. These samples are then available to address research questions that are central to the interests of the IADRC. In addition, these samples are available for collaborative studies, thereby enhancing the power of all ADRC studies focused on disease susceptibility, onset and progression. In this application, the GBBC will expand its scope to also support functional studies through the targeted development of induced pluripotent stem cells (iPSCs). The GBBC will leverage both the IUSM-JAX-Pitt MODEL-AD Center, whose goal is to develop, characterize and test therapeutic strategies in mouse models of AD and the IUSM-Purdue TREAT AD Center, whose goal is to integrate sophisticated capabilities for early drug discovery, to contribute to a broader study of AD target hypotheses (beyond Aβ) to generate new classes of potential therapeutics. The IADRC GBBC proposes the following specific aims: 1. Obtain longitudinal biospecimen samples from all subjects seen in the Clinical Core and support local and national research studies. 2. Obtain biomarker data to support ongoing studies of cognitive impairment and dementia. 3. Establish iPSCs from select IADRC participants to support local research studies. 4. Provide education in the areas of genetics and biomarkers.

项目摘要 - 遗传学，生物标志物和生物传播核心（GBBC）印第安纳州阿尔茨海默氏病研究中心（IADRC）具有创新的悠久历史分子和成像基因组学研究，并将继续关注遗传学的作用和其他类型的生物标志物作为临床轨迹的预测因素患有阿尔茨海默氏病（AD）和其他痴呆症的人以及临床前的人和前驱阶段，例如主观认知下降（SCI）和轻度认知障碍（MCI）。遗传学，生物标志物和生物传播核心（GBBC）在通过收集统一的生物测量，协调的协调来支持这一整体重点遗传数据和基于血液的生物标志物的产生。 GBBC还支持多个通过广泛的标本和数据共享国家的努力。 GBBC利用印第安纳州独特的患者人群和基因组资源大学医学院支持每个核心以及IADRC的整体目标。 GBBC通过从多样化的研究小组。然后可以使用这些样本来解决研究问题是IADRC利益的核心。另外，这些样品可用于协作研究，从而增强了所有集中于疾病的ADRC研究的力量敏感性，发作和进展。在此应用程序中，GBBC将扩大其范围，也通过诱导多能干细胞（IPSC）的靶向发展。 GBBC将利用这两个 IUSM-JAX-PITT模型中心的目标是开发，表征和测试 AD和IUSM-Purdue Treat Ad Center的鼠标模型中的治疗策略，谁目标是整合早期药物发现的复杂能力，为更广泛的贡献做出贡献研究AD靶假设（Aβ之外）的研究以产生新的潜在治疗。 IADRC GBBC提出以下具体目的： 1。从临床核心中所有受试者和支持本地和国家研究。 2。获取生物标志物数据以支持对认知障碍和痴呆症的持续研究。 3。从某些IADRC参与者中建立IPSC，以支持本地研究。 4。在遗传学和生物标志物领域提供教育。